CGT4HIVCure 2015 is grateful for the generous support of our corporate sponsors:
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Our portfolio of 16 marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill.
amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS related public policy. Since 1985, amfAR has invested more than $450 million in its programs and has awarded more than 3,300 grants to research teams worldwide.
Among many accomplishments, amfAR supported early studies that led to the development of four of the six main classes of anti-HIV drugs that allow people living with HIV/AIDS to live longer, healthier lives, and amfAR pioneered the research that led to the use of antiretroviral drugs to prevent mother-to-child transmission of HIV.
Today amfAR’s research focus is on the search for a cure for HIV/AIDS. Following the establishment of the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010, amfAR launched the Countdown to a Cure for AIDS Initiative. Backed by a $100 million research investment strategy, the Countdown is aimed at developing the scientific basis for a cure by 2020.
Sangamo BioSciences, Inc. is a clinical-stage biotechnology company, based in the San Francisco Bay Area, focused on Engineering Genetic CuresTM for monogenic and infectious diseases. Sangamo is deploying its proprietary zinc finger DNA-binding protein (ZFP) technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGFAAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia A and B, Huntington’s disease, and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation.
Sponsorship opportunities are available for the Conference on Cell and Gene Therapy for HIV Cure 2015.
Inquiries may be sent to firstname.lastname@example.org.